272 related articles for article (PubMed ID: 33986731)
1. Outcome of Patients With Metastatic Lung Neuroendocrine Tumors Submitted to First Line Monotherapy With Somatostatin Analogs.
Lenotti E; Alberti A; Spada F; Amoroso V; Maisonneuve P; Grisanti S; Baggi A; Bianchi S; Fazio N; Berruti A
Front Endocrinol (Lausanne); 2021; 12():669484. PubMed ID: 33986731
[TBL] [Abstract][Full Text] [Related]
2. Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids.
Sullivan I; Le Teuff G; Guigay J; Caramella C; Berdelou A; Leboulleux S; Déandréis D; Hadoux J; Ducreux M; Duvillard P; Adam J; Scoazec JY; Baudin E; Planchard D
Eur J Cancer; 2017 Apr; 75():259-267. PubMed ID: 28242503
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs: a retrospective study.
Ida H; Honma Y; Hirano H; Shoji H; Iwasa S; Okita N; Takashima A; Kato K; Fukuda T; Boku N
Invest New Drugs; 2019 Jun; 37(3):573-578. PubMed ID: 30267338
[TBL] [Abstract][Full Text] [Related]
4. Outcome Analysis of First-line Somatostatin Analog Treatment in Metastatic Pulmonary Neuroendocrine Tumors and Prognostic Significance of
Bongiovanni A; Recine F; Riva N; Foca F; Liverani C; Mercatali L; Nicolini S; Pieri F; Amadori D; Ibrahim T
Clin Lung Cancer; 2017 Jul; 18(4):415-420. PubMed ID: 27956089
[TBL] [Abstract][Full Text] [Related]
5. Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study.
Dasari A; Bergsland EK; Benson AB; Cai B; Huynh L; Totev T; Shea J; Duh MS; Neary MP; Dagohoy CG; Shih BE; Maurer VE; Chan J; Kulke MH
Oncologist; 2019 Aug; 24(8):1066-1075. PubMed ID: 30610008
[TBL] [Abstract][Full Text] [Related]
6. Antiproliferative Effect of Above-Label Doses of Somatostatin Analogs for the Management of Gastroenteropancreatic Neuroendocrine Tumors.
Diamantopoulos LN; Laskaratos FM; Kalligeros M; Shah R; Navalkissoor S; Gnanasegaran G; Banks J; Smith J; Jacobs B; Galanopoulos M; Mandair D; Caplin M; Toumpanakis C
Neuroendocrinology; 2021; 111(7):650-659. PubMed ID: 32541155
[TBL] [Abstract][Full Text] [Related]
7. Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors.
Allaw MB; Switchenko JM; Khalil L; Wu C; Alese OB; Akce M; Draper A; Jones AT; El-Rayes B; Shaib W
Oncology; 2022; 100(3):131-139. PubMed ID: 35078191
[TBL] [Abstract][Full Text] [Related]
8. External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study.
Jimenez-Fonseca P; Carmona-Bayonas A; Lamarca A; Barriuso J; Castaño A; Benavent M; Alonso V; Riesco MDC; Alonso-Gordoa T; Custodio A; Sanchez Canovas M; Hernando J; López C; La Casta A; Fernandez Montes A; Marazuela M; Crespo G; Diaz JA; Feliciangeli E; Gallego J; Llanos M; Segura A; Vilardell F; Percovich JC; Grande E; Capdevila J; Valle J; Garcia-Carbonero R
Neuroendocrinology; 2022; 112(1):88-100. PubMed ID: 33508849
[TBL] [Abstract][Full Text] [Related]
9. Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less.
Özaslan E; Karaca H; Koca S; Sevinç A; Hacioğlu B; Özkan M; Özçelik M; Duran AO; Hacibekiroğlu İ; Yildiz Y; Tanriverdi Ö; Menekşe S; Aksoy A; Bozkurt O; Urvay S; Uysal M; Demir H; Çiltaş A; Dane F
Anticancer Drugs; 2017 Feb; 28(2):222-229. PubMed ID: 27768606
[TBL] [Abstract][Full Text] [Related]
10. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study.
Kulke MH; Benson AB; Dasari A; Huynh L; Cai B; Totev T; Roesner N; Duh MS; Neary MP; Maurer VE; Shih BE; Dagohoy CG; Chan J; Bergsland EK
Oncologist; 2019 Aug; 24(8):1056-1065. PubMed ID: 30606883
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.
Strosberg JR; Yao JC; Bajetta E; Aout M; Bakker B; Hainsworth JD; Ruszniewski PB; Van Cutsem E; Öberg K; Pavel ME
Endocr Relat Cancer; 2015 Dec; 22(6):933-40. PubMed ID: 26373569
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
[TBL] [Abstract][Full Text] [Related]
13. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.
Faiss S; Pape UF; Böhmig M; Dörffel Y; Mansmann U; Golder W; Riecken EO; Wiedenmann B;
J Clin Oncol; 2003 Jul; 21(14):2689-96. PubMed ID: 12860945
[TBL] [Abstract][Full Text] [Related]
14. Association between somatostatin analogues and diabetes mellitus in gastroenteropancreatic neuroendocrine tumor patients: A Surveillance, Epidemiology, and End Results-Medicare analysis of 5235 patients.
Ni K; Yang JY; Baeg K; Leiter AC; Mhango G; Gallagher EJ; Wisnivesky JP; Kim MK
Cancer Rep (Hoboken); 2021 Oct; 4(5):e1387. PubMed ID: 33835729
[TBL] [Abstract][Full Text] [Related]
15. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life.
Faggiano A; Carratù AC; Guadagno E; Tafuto S; Tatangelo F; Riccardi F; Mocerino C; Palmieri G; Damiano V; Siciliano R; Leo S; Mauro A; Tozzi LF; Battista C; De Rosa G; Colao A
Oncotarget; 2016 Feb; 7(5):5538-47. PubMed ID: 26701729
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic approach to subcutaneous nodules in patients with neuroendocrine tumours treated with depot somatostatin analogs: a cross-sectional study.
Chicharro P; Paniagua A; Rodríguez-Jiménez P; Ibañes S; Cortina B; Riveiro J; Sampedro-Núñez MÁ; Fraga J; Marazuela M; Daudén E
J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):1887-1892. PubMed ID: 29377286
[TBL] [Abstract][Full Text] [Related]
18. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.
Cives M; Kunz PL; Morse B; Coppola D; Schell MJ; Campos T; Nguyen PT; Nandoskar P; Khandelwal V; Strosberg JR
Endocr Relat Cancer; 2015 Feb; 22(1):1-9. PubMed ID: 25376618
[TBL] [Abstract][Full Text] [Related]
19. Patterns of Care Among Real-World Patients with Metastatic Neuroendocrine Tumors.
Klink AJ; Feinberg B; Yu HT; Ray D; Pulgar S; Phan A; Vinik A
Oncologist; 2019 Oct; 24(10):1331-1339. PubMed ID: 31015313
[TBL] [Abstract][Full Text] [Related]
20. Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study.
Carmona-Bayonas A; Jiménez-Fonseca P; Lamarca Á; Barriuso J; Castaño Á; Benavent M; Alonso V; Riesco-Martínez MDC; Alonso-Gordoa T; Custodio A; Sánchez Cánovas M; Hernando Cubero J; López C; Lacasta A; Fernández Montes A; Marazuela M; Crespo G; Escudero P; Diaz JÁ; Feliciangeli E; Gallego J; Llanos M; Segura Á; Vilardell F; Percovich JC; Grande E; Capdevila J; Valle JW; García-Carbonero R
J Clin Oncol; 2019 Oct; 37(28):2571-2580. PubMed ID: 31390276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
